Skip to main content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC:
Get the latest research information from NIH:

Profile Image

Senior Investigator

Bibiana Bielekova, M.D.

Neuroimmunological Diseases Section

Laboratory of Clinical Immunology and Microbiology
Building 10 Room 5N248
10 Center Drive MSC1444
Bethesda MD 20892
Office: (301) 761-5333

Dr. Bielekova received an M.D. in 1993 from Comenius University in Bratislava, Slovakia. After a medical internship at SUNY Downstate Medical Center in Brooklyn and a neurology residency at Boston University, she did a 3-year postdoctoral research fellowship at the NINDS Neuroimmunology Branch (NIB). She remained at NIB for an additional 5 years as a staff physician, focusing on development of novel therapies for MS. In 2005, she became associate professor of neurology with tenure and director of the Waddell Center for MS at University of Cincinnati. In 2008, she moved back to NINDS as an investigator. In 2018, Dr. Bielekova transferred as a senior investigator to NIAID. Her laboratory is studying mechanisms of immunoregulation and immune-mediated CNS tissue injury in MS and other neuroimmunological diseases with a long-term goal of developing effective therapies. In addition, Dr. Bielekova is a principal investigator on several innovative protocols including adaptively designed Phase I/II clinical trials.

Major Areas of Research

  • Development of combinatorial biomarkers for reliable measurement of pathophysiological processes (e.g., inflammation, neurodegeneration) in patients with immune-mediated diseases of the central nervous system, especially multiple sclerosis (MS)
  • Validation of MS disease mechanisms and therapeutic targets within the context of interventional clinical trials and longitudinal follow-up of patients on FDA-approved disease-modifying treatments.
  • Identification of biomarker signatures that can predict a drug’s efficacy on clinical outcomes and development of algorithms that optimize therapeutic selections by combining patients’ pre-treatment cerebrospinal fluid (CSF) biomarker profiles with newly acquired knowledge of the drug’s intrathecal effects as measured by CSF biomarkers.

The mission of the Neuroimmunological Diseases Section is to understand, diagnose, prognosticate, and cure neuroimmunological diseases.

Through understanding of the mechanisms that participate in central nervous system (CNS) injury and those that have neuroprotective functions, we aim to develop effective therapies for neuroimmunological diseases. Because observational studies cannot determine causal relationships, we use proof-of-principle interventional trials supported by biomarker/mechanistic studies and mathematical modeling to investigate major hypotheses about the pathophysiology of MS.

Our studies revealed that relapsing-remitting MS (RRMS) and progressive MS are categorical descriptions of early versus evolved stages of the identical continuous disease process characterized by aberrant activation of adaptive immunity that targets CNS tissue, which evolves by progressive intrathecal compartmentalization and terminal differentiation of T and B cells to a treatment-resistant stage. The multiplicity of potential pathogenic processes in evolved MS makes it unlikely that a single therapeutic agent will have major clinical efficacy. Analogous to cardiovascular diseases, effective therapy will require combinations of therapeutics that target patient-specific drivers of disability. We believe that the development of such combination treatments requires the ability to reliably measure the diverse CNS pathophysiological processes in living people and thereby define process-specific biomarkers to use as outcomes in Phase II trials. Indeed, using CSF biomarkers and systems biology methodology we have defined (and validated in an independent cohort) molecular signature(s) that differentiate MS from other CNS diseases and those that can reliably measure the levels of intrathecally compartmentalized inflammation and CNS tissue destruction. Our goal is to formulate (and validate) a framework where a combinatorial CSF biomarker(s) can provide reliable diagnostic, prognostic, and therapeutically predictive information that will empower neurologists to practice precision medicine.

Clinical Research Protocol

Staff Image
  • Chris Barbour, Ph.D.
    Postdoctoral Visiting Fellow

  • Paavali Hannikainen, B.S.
    Post baccalaureate Fellow

  • Tiffany Hauser, MBA, BSN
    Research and Regulatory Nurse

  • Kayla Jackson, B.S.
    Post baccalaureate Fellow

  • Peter Kosa, Ph.D.
    Contract Scientist

  • Raj Masvekar, Ph.D.
    Postdoctoral Visiting Fellow

  • Linh Pham, B.S.
    Post baccalaureate Fellow

  • Jon Phillips, B.S.
    Post baccalaureate Fellow

  • Elena Romm, M.Sc
    Research Chemist

  • Mary Sandford, MSN
    Nurse Practitioner

  • Mihael Varosanec, M.D.
    Postdoctoral Visiting Fellow

  • Alison Wichman, M.D.

  • Michelle Woodland
    Patient Care Coordinator

  • 1) Kosa P, Barbour C, Wichman A, Sandford M, Greenwood M, Bielekova B (2018)
  • NeurEx: digitalized neurological examination offers a novel high-resolution disability scale
  • Ann Clin Transl Neurol, 2018 Sep 24;5(10), 1241-1249
  • 2) Barbour C, Kosa P, Komori M, Tanigawa M, Masvekar R, Wu T, Johnson K, Douvaras P, Fossati V, Herbst R, Wang Y, Tan K, Greenwood M, Bielekova B (2017)
  • Molecular-based diagnosis of multiple sclerosis and its progressive stage
  • Ann Neurol, 2017 Nov;82(5), 795-812
  • 3) Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017)
  • Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
  • Front Neurol, 2017 Nov 10;8, 577
  • 4) Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, Matsuura E, Maric D, Waldmann TA, Bielekova B (2017)
  • A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
  • Nat Med, 2011 May;17(5), 604-9
  • 5) Komori M, Blake A, Greenwood M, Lin YC, Kosa P, Ghazali D, Winokur P, Natrajan M, Wuest SC, Romm E, Panackal AA, Williamson PR, Wu T, Bielekova B (2015)
  • Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis
  • Ann Neurol, 2015 Jul;78(1), 20-Mar
  • 6) Natrajan MS, de la Fuente AG, Crawford AH, Linehan E, Nuñez V, Johnson KR, Wu T, Fitzgerald DC, Ricote M, Bielekova B, Franklin RJ (2015)
  • Retinoid X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination
  • Brain, 2015 Dec;138(Pt 12), 3581-97
View Pubmed Publication